Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia — RECOVER  

Schizophrenia Clinical Trial

Official title: Phase 3, Randomized, 28 Days, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Brilaroxazine (RP5063) in Subjects With Schizophrenia, Followed by a 52-Week Open-label Extension

Status Recruiting

Clinical Trial Summary

This study is to evaluate the effect and safety of Brilaroxazine in patients with acute schizophrenia compared to the placebo short and long-term. Brilaroxazine will be given at fixed doses of 15 mg or 50 mg once daily over 4 weeks, then in the long-term flexible doses 15-50mg daily over a period of 52 weeks.

Clinical Trial Description

This is a randomized, double-blind (DB), placebo-controlled, multicenter study to assess the efficacy and safety of RP5063 (brilaroxazine) at fixed doses of 15 mg or 50 mg, administered once daily (OD) for 28 days (28 days DB treatment) in subjects with an acute exacerbation of schizophrenia. The study further will assess the safety of RP5063 (brilaroxazine) at flexible doses of either 15, 30 or 50 mg administered OD in an Open Label (OL) treatment over a period of 52 weeks (52-week OL treatment part), in subjects with stable schizophrenia. The OL treatment will have 2 populations of stable schizophrenia: DB rollover and de novo subjects.

The study comprises 2 parts: a 28-day DB treatment, followed by 52 weeks OL treatment.

The total duration of the study is 56 weeks (28 days/4 weeks DB treatment and 52-weeks OL treatment). ;

Related Conditions & MeSH terms

• Schizophrenia

• NCT number: NCT05184335
• Study type: Interventional
• Source: Reviva Pharmaceuticals
• Contact: Medical Director
• Phone: +1 4085018881
• Email: medicaldirector@revivapharma.com
• Status: Recruiting
• Phase: Phase 3
• Start date: January 24, 2022
• Completion date: October 31, 2024